Hyderabad: Bharat Biotech, a city based biotechnology firm, on Monday announced the launch of India's first indigenously developed cell culture H1N1 Swine Flu Vaccine under the brand name HNVAC.
HNVAC is the vaccine manufactured in cell culture, a highly sterile and controlled manufacturing process instead of eggs, the company said in a release.
The vaccine was tested extensively in one of the largest Phase I, II and III clinical trials for flu vaccines in India and has proved that it is safe and well tolerated, it said.
Bharat Biotech's Chairman and Managing Director, Dr Krishna Ella said the company is proud to have developed and offered this vaccine with the best USFDA recommended cell culture technology for Indian consumers.
"While there's certainly widespread and growing concern around H1N1, there are number of people who did not get a flu shot last year. Our goal right now is to make the flu vaccine easily accessible and at affordable cost to high-risk groups," he said.
He said the company has been exploring ways in which Bharat Biotech can assist consumers and government agencies throughout this and subsequent flu season to get HNVAC flu shot.
Bharat Biotech received the approval from the Drugs Controller General of India earlier this month to launch HNVAC vaccine. It was developed with approved strains from WHO and CDC Atlanta.
Bharat Biotech expects the demand for flu vaccines in India to rise in view of growing consumer awareness about the disease. Consumers are more concerned about getting the flu than they were a year ago, the release said, adding HNVAC will be made available in the private market and through government procurement agencies.